{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:40:18Z","timestamp":1766407218500,"version":"3.37.3"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study evaluated the effectiveness and cost-effectiveness of baricitinib, tofacitinib, and upadacitinib regimens, compared to conventional synthetic disease-modifying antirheumatic drug (csDMARD) alone, among Japanese patients with moderate-to-severe rheumatoid arthritis (RA) inadequately responsive to csDMARD, measured in terms of number needed to treat (NNT) and cost per responder (CPR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Efficacy data were derived from two recent network meta-analyses among global and Japanese population. The cost perspective was that of the Japanese Health Service. Both NNT and CPR were based on disease activity score for 28 joints with C-reactive protein (DAS28-CRP) remission and American College of Rheumatology (ACR) 20\/50\/70 at 12 and 24\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over 12\u2009weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 [USD 16,361], respectively, for upadacitinib 15\u2009mg\u2009+\u2009csDMARD. The equivalent results were 6.0 and JPY 2,691,684 [USD 24,470] for baricitinib 4\u2009mg\u2009+\u2009csDMARD and 5.6 and JPY 2,507,152 [USD 22,792] for tofacitinib 5\u2009mg\u2009+\u2009csDMARD. Similar rankings were observed at 24\u2009weeks and for other outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Upadacitinib 15\u2009mg was associated with the lowest NNT and CPR among the three Janus kinase inhibitors used in treatment regimens for Japanese patients with moderate-to-severe RA inadequately responsive to csDMARD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac015","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T08:53:38Z","timestamp":1644483218000},"page":"54-63","source":"Crossref","is-referenced-by-count":3,"title":["Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan"],"prefix":"10.1093","volume":"33","author":[{"given":"Tatsuya","family":"Atsumi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Asakura","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Doi","sequence":"additional","affiliation":[{"name":"AbbVie GK , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Sawant","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-9466","authenticated-orcid":false,"given":"Isao","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"AbbVie GK , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Sasaki","sequence":"additional","affiliation":[{"name":"AbbVie GK , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"2023011210570886200_R1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023011210570886200_R2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102776","article-title":"Rheumatoid arthritis: extra-articular manifestations and comorbidities","volume":"20","author":"Figus","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023011210570886200_R3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023011210570886200_R5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/annrheumdis-2019-216243","article-title":"Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era","volume":"79","author":"Hsieh","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023011210570886200_R6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1080\/14397595.2017.1361893","article-title":"Productivity loss of Japanese patients with rheumatoid arthritis \u2013 a cross-sectional survey","volume":"28","author":"Sruamsiri","year":"2018","journal-title":"Mod Rheumatol"},{"volume-title":"2020 Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis","year":"2021","author":"Japan College of Rheumatology","key":"2023011210570886200_R7"},{"key":"2023011210570886200_R8","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023011210570886200_R9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14397595.2021.1910615","article-title":"Geographic variations in rheumatoid arthritis treatment in Japan: a nationwide retrospective study using the national database of health insurance claims and specific health checkups of Japan","volume":"32","author":"Nakajima","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40259-016-0190-5","article-title":"Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis","volume":"30","author":"Nakayamada","year":"2016","journal-title":"BioDrugs"},{"key":"2023011210570886200_R12","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology"},{"key":"2023011210570886200_R13","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"2023011210570886200_R14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/14397595.2020.1847776","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-na\u00efve Japanese patients with rheumatoid arthritis: a sub-analysis of the phase 3 SELECT-EARLY study","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210570886200_R16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2023011210570886200_R17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023011210570886200_R18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023011210570886200_R19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"2023011210570886200_R20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"2023011210570886200_R21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Eng L J Med"},{"key":"2023011210570886200_R22","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023011210570886200_R23","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1007\/s12325-020-01303-3","article-title":"Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis","volume":"37","author":"Pope","year":"2020","journal-title":"Adv Ther"},{"key":"2023011210570886200_R24","first-page":"P2","article-title":"Comparative efficacy of Janus kinase inhibitors in the treatment of Japanese patients with moderate-to-severe rheumatoid arthritis: a network meta-analysis. 2020","author":"Atsumi","year":"2020"},{"key":"2023011210570886200_R25","first-page":"1","article-title":"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess (Winchester, England)"},{"article-title":"Baricitinib for Moderate to Severe Rheumatoid Arthritis: Technology Appraisal Guidance","year":"2017","author":"National Institute for Health Care and Excellence (NICE)","key":"2023011210570886200_R26"},{"article-title":"Upadacitinib for Moderate to Severe Rheumatoid Arthritis","year":"2020","author":"National Institute for Health Care and Excellence (NICE)","key":"2023011210570886200_R27"},{"key":"2023011210570886200_R28","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1007\/s12325-021-01642-9","article-title":"Authors\u2019 response to letter to the editor regarding comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis","volume":"38","author":"Pope","year":"2021","journal-title":"Adv Ther"},{"key":"2023011210570886200_R29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/14397595.2018.1553489","article-title":"Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post hoc analysis of clinical trial data","volume":"29","author":"Takeuchi","year":"2019","journal-title":"Mod Rheumatol"},{"author":"Pharmaceuticals and Medical Devices Agency [PMDA]","key":"2023011210570886200_R31","article-title":"Olumiant Tablets Product Insert (in Japanese)"},{"author":"Pharmaceuticals and Medical Devices Agency [PMDA]","key":"2023011210570886200_R32","article-title":"Xeljanz tablets Product Insert (in Japanese)"},{"author":"Pharmaceuticals and Medical Devices Agency [PMDA]","key":"2023011210570886200_R33","article-title":"Rinvoq Tablets Product Insert (in Japanese)"},{"key":"2023011210570886200_R34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"2023011210570886200_R35","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1177\/0962280219890635","article-title":"Systematic analysis of the number needed to treat","volume":"29","author":"Vancak","year":"2020","journal-title":"Stat Methods Med Res"},{"author":"Bank of Japan","key":"2023011210570886200_R36","article-title":"List of Exchange Rates for Reporting Ministerial Ordinance (in Japanese)"},{"article-title":"Japanese National Health Insurance Drug Price list (in Japanese)","year":"2020","author":"Ministry of Health, Labour and Welfare [MHLW]","key":"2023011210570886200_R37"},{"author":"Pharmaceuticals and Medical Devices Agency [PMDA]","key":"2023011210570886200_R38","article-title":"Rheumatrex Capsules Product Insert (in Japanese)"},{"key":"2023011210570886200_R39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"author":"AbbVie","key":"2023011210570886200_R40","article-title":"The Common Technical Document of Rinvoq 15mg and 7.5mg Tablets (in Japanese)"},{"article-title":"Revision of the Medical Fees 2020 Update (in Japanese)","year":"2020","author":"Ministry of Health, Labour and Welfare [MHLW]","key":"2023011210570886200_R41"},{"key":"2023011210570886200_R42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"2023011210570886200_R43","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheumat Dis"},{"key":"2023011210570886200_R44","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"author":"United States Food and Drug Administration (FDA)","key":"2023011210570886200_R45","article-title":"Highlights of Prescribing Information: RINVOQ (upadacitinib) Extended-Release Tablets, for Oral Use"},{"key":"2023011210570886200_R46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543784.2014.918604","article-title":"Selective JAK inhibitors in development for rheumatoid arthritis","volume":"23","author":"Norman","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"2023011210570886200_R47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","article-title":"Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023011210570886200_R48","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.23733","article-title":"The importance of reporting disease activity states in rheumatoid arthritis clinical trials","volume":"58","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023011210570886200_R49","doi-asserted-by":"crossref","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023011210570886200_R50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3109\/s10165-012-0729-3","article-title":"Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R51","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1007\/s12325-021-01641-w","article-title":"Letter to the editor regarding comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis","volume":"38","author":"Fakhouri","year":"2021","journal-title":"Adv Ther"},{"key":"2023011210570886200_R52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14397595.2017.1317383","article-title":"Design characteristics of the Corrona Japan rheumatoid arthritis registry","volume":"28","author":"Yamanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023011210570886200_R53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/14397595.2018.1554228","article-title":"Disease activity, treatment and long-term prognosis of adult juvenile idiopathic arthritis patients compared with rheumatoid arthritis patients","volume":"30","author":"Matsumoto","year":"2020","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac015\/42748485\/roac015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/54\/48626536\/roac015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/54\/48626536\/roac015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:14:42Z","timestamp":1673525682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/1\/54\/6526016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac015","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"type":"print","value":"1439-7595"},{"type":"electronic","value":"1439-7609"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,2,10]]}}}